Published in Women's Health Weekly, December 15th, 2005
According to researchers from Austria, "Tamoxifen has been the standard adjuvant treatment for postmenopausal women with hormone-responsive early breast cancer for more than 20 years. However, the third-generation aromatase inhibitor anastrozole has proven efficacy and tolerability benefits compared with tamoxifen when used as initial adjuvant therapy."
R. Jakesz and colleagues "investigated whether women who have received a period of adjuvant tamoxifen would benefit from being switched to anastrozole. They presented a combined analysis of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly